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Background: Antimicrobial properties of the anti-inflammatory neuropeptide VIP are limited by its unstable nature.
Results:TheVIP derivatives protected against polymicrobial sepsis and cutaneous leishmaniasis by selectively killing pathogens
through membrane-disrupting mechanisms.
Conclusion: Modification of critical residues in the native VIP sequence generates stable peptides with potent antimicrobial
activities in vitro and in vivo.
Significance: This work indicates a molecular rationale for designing new agents against drug-resistant infectious diseases.
Vasoactive intestinal peptide (VIP) is an anti-inflammatory
neuropeptide recently identified as a potential antimicrobial
peptide. To overcome themetabolic limitations ofVIP,wemod-
ified the native peptide sequence and generated two stable syn-
thetic analogues (VIP51 and VIP51(6–30)) with better antimi-
crobial profiles. Herein we investigate the effects of both VIP
analogues on cell viability, membrane integrity, and ultrastruc-
ture of various bacterial strains and Leishmania species. We
found that the two VIP derivatives kill various non-pathogenic
and pathogenic Gram-positive and Gram-negative bacteria as
well as the parasite Leishmania major through a mechanism
that depends on the interaction with certain components of the
microbial surface, the formation of pores, and the disruption of
the surfacemembrane. The cytotoxicity of the VIP derivatives is
specific for pathogens, because they do not affect the viability of
mammalian cells. Docking simulations indicate that the chemi-
cal changes made in the analogues are critical to increase their
antimicrobial activities. Consequently, we found that the native
VIP is less potent as an antibacterial and fails as a leishmani-
cidal. Noteworthy from a therapeutic point of view is that treat-
ment with both derivatives increases the survival and reduces
bacterial load and inflammation inmicewith polymicrobial sep-
sis. Moreover, treatment with VIP51(6–30) is very effective at
reducing lesion size andparasite burden in amodel of cutaneous
leishmaniasis. These results indicate that the VIP analogues
emerge as attractive alternatives for treating drug-resistant
infectious diseases and provide key insights into a rational
design of novel agents against these pathogens.
Resurgence of infections is a current worldwide problem.
People from both the poorest areas and the richest countries
are continuously faced with pathogens that cause different
infectious diseases. For example, neglected tropical parasitic
diseases affect more than 1 billion people (1). On the other
hand, uncontrolled response to bacterial dissemination in sep-
sis is the third leading cause of death in developed societies,
affecting 18million people (2). Current conventional drugs suf-
fer from loss of function and severe adverse effects. This high-
lights the urgent need for new strategies to combat microbial
infections. The search for novel anti-infective therapies has
lately focused on endogenous cationic peptides that regulate
immunological and physiological homeostatic parameters in
the context of the host response to infectious diseases. These
molecules, termed host defense peptides, have emerged as
potential therapeutic candidates. Recently, some neuropep-
tides, which are pleiotropic and integral components of the
neuroendocrine system, have been recognized as host defense
peptides (3).
Vasoactive intestinal peptide (VIP)2 is a neuropeptide
belonging to the glucagon/secretin superfamily (4) that is
widely distributed in many tissues and organs of the body,
including brain, heart, lung, digestive and genitourinary tracts,
immune cells, and thyroid gland (5). Through its binding to
specific receptors, VIP elicits a broad spectrum of biological
functions in organisms, including neuroprotection, relaxation
of smooth muscle, regulation of exocrine and endocrine secre-
tions, and modulation of the immune response (6). As a conse-
quence, many studies have proven the therapeutic potential of
VIP in several diseases, especially in inflammatory, respiratory,
and neurodegenerative disorders (7–13). Moreover, it was
recently reported that VIP exerts a direct antimicrobial activity
against a variety of pathogens, including bacteria (14) and Afri-
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can trypanosomatids (15), although the involved mechanisms
remain largely unclear. Similar to other neuropeptides (3), VIP
shares some properties with antimicrobial peptides, such as
small size, cationic charge, and amphipathic design (Table 1). In
addition, VIP is abundantly present in physical barriers of the
body (skin and mucosa), physiological fluids (maternal milk,
tears, and saliva), and immunoprivileged sites (eyes, testis, and
ovaries) (5). Furthermore, VIP is released under microbial-in-
duced inflammation (15, 16), and it has immunomodulatory
functions. These findings support a new role for VIP as a poten-
tial host defense peptide (17).However, the poor stability ofVIP
after systemic administration and its poor penetration to the
desired site of action have limited its clinical application. To
overcome these shortcomings, the development of efficacious
VIP analogues and several drug delivery systems has been
attempted. Thus, amino acidmodifications/substitutions in the
VIP sequence, its combination with endopeptidase inhibitors,
design of VIP formulations based on protected nanoparticles or
micelles, and even VIP-secreting viral vectors have improved
the half-life of the neuropeptide and its delivery in the targeted
tissue (18). Specifically, following the strategy of amino acid
substitutions, Onoue et al. (19–21) recently generated various
VIP derivatives in inhalable formulations that showed
improved metabolic stability and higher therapeutic efficacy
than the native VIP in models of inflammatory pulmonary dis-
eases. The analysis of the sequence and structure of one of these
VIP derivatives named IK312551 and referred to herein as
VIP51 (Table 1 and supplemental Fig. S1) revealed that the
chemical modifications made in the VIP analogue increased its
cationic charge, hydrophobicity index, and percentage of -he-
lix (Table 1), improving its predictable profile as antimicrobial
peptide in comparison with native VIP.
The aimof this studywas to develop a rational design ofmore
efficient therapeutic strategies against microbial diseases.
Therefore, we investigated in vitro and in vivo the antimicrobial
and immunomodulatory activities of VIP51 against different
pathogens. Moreover, to discriminate in vivo between its direct
effect against pathogens and its potential indirect effect in VIP
receptor-expressing mammalian cells, we evaluated the effect
in this systemof a new chemically designed truncated version of
VIP51 (named VIP51(6–30)), which lacks the first five N-ter-
minal residues that are essential to activate the VIP receptor
(22).
EXPERIMENTAL PROCEDURES
Peptides—VIP was purchased from American Peptide, and
the VIP derivatives (VIP51 and VIP51(6–30)) and their FITC-
labeled forms were chemically synthesized by GeneScript. All
peptides were initially reconstituted in sterile water (Bio-Rad)
and further diluted in phosphate-buffered saline (PBS; 1.2 mM
KH2PO4, 8.1 mMNa2HPO4, 130mMNaCl, 2.6 mMKCl, pH 7.0)
or the corresponding culture medium at the indicated concen-
trations before their use.
Microorganisms and Growth Conditions—Streptococcus
mutans (CECT 479) and Enterococcus faecalis (CECT 184)
were grown under shaking in brain heart infusion broth (Difco)
at 37 °C,Micrococcus luteus (CECT243) andEnterobacter aero-
genes (CECT 684) inNutrient I at 30 °C, Escherichia coli (CECT
45) in Nutrient I at 37 °C, and Pseudomonas aeruginosa (CECT
108) and Pseudomonas pseudoalcaligenes (CECT318) inNutri-
ent II at 37 and 26 °C, respectively. These strains were obtained
from the Spanish Center for Type Culture Collection and pre-
pared and grown following supplier instructions for biological
group risk 1 (non-pathogenic) and 2 (pathogenic). E. coli Top
10 (Invitrogen) and E. coli K-12 mutants deficient in LPS syn-
thesis (E. coli Genetic Stock Center, Yale University, New
Haven, CT) were cultured under shaking in Luria broth
medium at 37 °C. Gram-negative bacteria isolated from the
peritoneum of septic mice were grown under shaking in Nutri-
ent I at 37 °C.
For L. major, we used two different wild type (WT) and
mutant strains: L.major Friedlin (MHOM/IL/80/Friedlin) clone
V1 and the lipophosphoglycan (LPG)-inducible mutant glf/
KiddGLF (23). In this inducible system, the synthesis of a key
galactofuranose residuewithin the LPG core is controlled using
a conditional “destabilization domain” fused to UDP-galacto-
pyranosylmutase in the WT L. major Friedlin V1 background.
In the presence of the inducer FK506 (or other rapamycin-like
analogues) UDP-galactopyranosylmutase is stabilized, and para-
sites make high levels of LPG, whereas in its absence, LPG is
reduced to background levels. The phosphoglycan (PG)-deficient
lpg2/ mutant (24) lacking a Golgi GDP-mannose transporter
required for PG synthesis was generated in a WT L.major LV39
clone 5 (Rho/SU/59/P) background. These cell lines and L. don-
ovani (MHOM/ET/67/HU3) promastigotes were cultured at
28 °C in M-199 medium (Invitrogen) supplemented with 40 mM
HEPES, 100 M adenosine, 0.77 M hemin, 10 M biopterin, and
10% heat-inactivated fetal bovine serum (FBS; Invitrogen). Pro-
mastigotes from Leishmania infantum (MHOM/ES/1993/BCN-
99), L. tropica 656 cl (MHOM/IS/1998/LRC), and L.mexicana
(MHOM/VE/1990/M9012) were grown in modified RPMI 1640
medium (Invitrogen) supplemented with 20% FBS at 28 °C
(L. infantum and L. tropica) and at 23 °C (L.mexicana).
Antimicrobial Assays—The bactericidal activity of VIP,
VIP51, and VIP51(6–30) was determined by incubation of a 5
Mconcentration of every peptide (unless other concentrations
are indicated) with 106 bacteria of each strain at mid-exponen-
tial growth phase in 100 l of PBS for 3 h, under shaking at the
indicated growth temperatures. We stopped the reaction by
adding ice-cold PBS (dilution 1:100) for 5 min, and then we
determined the number of cfu/ml after overnight incubation on
agar dishes. Results were expressed as a percentage of bacterial
survival, (cfu after peptide treatment/cfu in the absence of pep-
tide) 100. Alternatively, bacterial viability was assayed using
the BacTiter-Glo microbial cell viability kit (Promega) as
described below.
To determine the antimicrobial activity of the peptides on
Leishmania promastigotes, we used the Alamar Blue reagent
(Sigma-Aldrich). Briefly, parasites were harvested at late expo-
nential phase and incubated in 96-well plates (100 l/well,
2.5  105 cells/ml) with serial peptide dilutions at the corre-
sponding growth temperatures. Peptides were also added 24 h
after initiating the culture. After 72 h of incubation, Alamar
Blue (0.11 mg/ml, 20 l/well) was added to cultures for 4 h and
then solubilized with 100 l of 3% SDS. Cell viability was
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assayed using a fluorescent plate reader (550 nm excitation, 590
nm emission).
When indicated, we adjusted the pH of PBS (for bacteria) or
the pH of HPMI buffer (20 mM HEPES, 132 mM NaCl, 3.5 mM
KCl, 0.5 mM MgCl2, 5 mM glucose, 1 mM CaCl2, pH 7.4; for
parasites) to acid (pH 5.0, pH 6.0) or basic (pH 8.0, pH 9.0)
conditions. To elucidate the effects of NaCl and MgCl2, the
bacteria-peptide and parasite-peptide reaction solution con-
sisted of PBS or HPMI buffer, respectively, supplemented with
20mM (physiological dose) or 50mMNaCl or with 1mM (phys-
iological dose) or 50 mM MgCl2. In these assays, bacteria and
parasites were incubated with the peptides for 3 and 4 h,
respectively.
We calculated EC50, which represents the concentration of
the peptide that reduces to 50% the viability of each bacteria
and parasite strain, by using four-parameter logistic curve-fit-
ting software (SigmaPlot).
Assays of Hemolysis and Cytotoxicity in Mammalian Cells—
The cytotoxicity assay was performed using mouse macro-
phages and splenocytes. Peritoneal macrophages were allowed
to adhere for 4 h in plastic in complete RPMI medium (RPMI
1640 containing 10% FBS, 2mM L-glutamine, 100 units/ml pen-
icillin, 100 mg/ml streptomycin, and 50 M -mercaptoetha-
nol) at 37 °C and then washed to remove non-adherent cells. A
cell suspension from spleen was obtained after mechanical
homogenization of the tissue and depletion of erythrocytes by
incubating the whole suspension with the erythrocyte lysis
buffer (0.15 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) for 10
min at room temperature. In both cases, macrophages and
splenocytes were seeded at 105 cells/well in 96-well microtiter
plates (100 l/well) and then incubated in the absence or pres-
ence of 12 MVIP51 and VIP51(6–30) for 72 h at 37 °C and 5%
CO2 atmosphere. Subsequently, AlamarBluewas added to each
well, and cell viability was determined.
To determine the hemolytic activity of VIP51 and VIP51(6–
30), we incubated mouse red blood cells (107 cells/well, 100 l)
obtained by cardiac puncture with a 12M concentration of the
peptides at 37 °C under shaking. After 1 h of incubation, sam-
ples were centrifuged (1,000  g, 10 min), and the concentra-
tion of hemoglobin in the supernatants was determined by
measuring the absorbance at 450 nm in a spectrophotometer
(Molecular Devices). We used samples with erythrocytes with-
out peptide treatment (control of basal hemolysis) and samples
with erythrocytes incubated with 1% Triton X-100 (control of
100% of hemolysis). We calculated the percentage of hemolysis
using the formula, % hemolysis  (absorbance units of the
erythrocytes exposed to peptide 100)/absorbance units of the
erythrocytes exposed to Triton X-100.
Binding Assay of the VIPDerivatives to Pathogens—To deter-
mine the binding capacity of VIP51 and VIP51(6–30) to both
pathogens, we co-treated 107 parasites with 8 M VIP51 or
VIP51(6–30) and 4MFITC-labeledVIP51 or FITC-VIP51(6–
30) in HPMI buffer or 5  106 E. coli with 3 M VIP51 or
VIP51(6–30) and 2MFITC-labeledVIP51 or FITC-VIP51(6–
30) in PBS. After different time periods of incubation, cells were
washed with ice-cold PBS, fixed in 2% formaldehyde, and
mounted in DAPI-containing ProLong medium (Molecular
Probes). Images were acquired with a fluorescence microscope
(Olympus IX81) and then deconvolved using the Huygens Pro-
fessional program (Scientific Volume Imaging).
Determination ofChanges in the PlasmaMembranePotential
and Permeabilization—To monitor changes in the plasma
membrane potential, we used bisoxonol (Molecular Probes), a
potentially sensitive anionic dye that increases fluorescence
after its insertion into the depolarized membrane. E. coli (5 
106) were cultured in 100 l of PBS at 37 °C for 1 h in the
absence or presence of 10 M VIP or the VIP derivatives. Log
phase L. major promastigotes (2 106) were cultured in 100l
of HPMI buffer in the absence or presence of 12 M VIP or the
VIP derivatives for different time periods at 28 °C. Then bacte-
ria and parasites were incubatedwith 0.025Mbisoxonol for 10
min at room temperature. Fluorescence changes were moni-
tored using a fluorescent plate reader (544 nm excitation, 584
nm emission). We used heated bacteria (10 min at 80 °C) and
parasites treated with 0.8 M gramicidin D as controls of max-
imal membrane depolarization.
To evaluate changes in the permeability of the plasma mem-
brane, we used SYTOX Green (Mr 600; Molecular Probes).
E. coli and L. major were pretreated with VIP or the VIP deriv-
atives as described above and then incubated with SYTOX
Green (0.05M for bacteria, 2M for parasite) at room temper-
ature. After 10 min, we measured the increase in fluorescence
(485 nm excitation, 520 nm emission) that reflects substantial
damage to the plasma membrane. We used heated bacteria (10
min at 80 °C) or 0.1%TritonX-100-treated parasites as controls
of maximal membrane permeabilization.
Electron Microscopy—E. coli (106; incubated with 5 M
VIP51 or VIP51(6–30) at 37 °C) or log phase promastigotes of
L. major (5 106; incubatedwith 12MVIP51 or VIP51(6–30)
at 28 °C) were harvested by centrifugation (2,000 g, 15min, at
4 °C) after different incubation time periods and then subjected
to the high pressure freezing method (25) and embedded in
Lowicryl HM20 resin. Ultrathin cryosections (65 nm) were
stained with 2% uranyl acetate (pH 7.0); collected with 2%
methylcellulose, 4% uranyl acetate (pH 7.0); and observed on a
JEM-1010 electron microscope (Jeol).
Determination of ATP Levels—Log phase L. major (2  106)
were treated with 12 M VIP and VIP derivatives in HPMI
buffer, as described above, and mixed with 50 l of CellTiter-
Glo reagent (Promega). After 10 min at room temperature,
luminescence signal, which is proportional to the ATP amount,
was monitored by an Infinite F200 microplate reader. We used
parasites incubated with 10 mM sodium azide, 5 mM 2-deoxy-
glucose, and 5 mM pyruvate as a control of ATP deprivation
(without glucose). ATP levels in bacteria cultures were deter-
mined by luminescence using the BacTiter-Glo microbial
cell viability kit (Promega) following the manufacturer’s
instructions.
Homology Modeling and Docking—The molecular modeling
of VIP used for simulations was obtained from the Protein Data
Bank (code 2RRH/2RRI). VIP51 and VIP51(6–30) structures
were resolved in the I-TASSER server (26) using the NMR con-
struction of human pituitary adenylate cyclase-activating poly-
peptide-38 (Protein Data Bank code 2D2P) as a template.
The confidence score for estimating the quality of predicted
models was calculated based on the significance of threading
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template alignments and the convergence parameters of the
structure assembly simulations. From all theoretical predicted
models found for each peptide, we selected those with the high-
est C-scores that indicate higher confidence (VIP, 0.18; VIP51,
0.28; VIP51(6–30), 0.29). We also determined the structural
similarity between structures using the TM-score parameter
(27) for each peptide: VIP, 0.74  0.11; VIP51 and VIP51(6–
30), 0.75  0.10 (TM  0.5 indicates correct topology, and
TM 0.17 indicates random similarity).
We conducted docking simulationswithAutoDockVina ver-
sion 4.2 (Scripps Research Institute, La Jolla, CA) (28), using
VIP, VIP51, and VIP51(6–30) as receptor molecule and the
bacterial lipopolysaccharide (LPS; Protein Data Bank code
1FI1) as the ligand. For all simulations, the grid size was x 80,
y 80, and z 80, centered at x5.7, y3.4, and z 6.6.
Each simulation contained eight conformations (exhaustive-
ness  8). For the analysis of interactions, we focused only on
polar hydrogen bonds between oligopeptides and LPS/trun-
cated LPSmutants.We calculated howmany times each amino
acid from VIP and the VIP analogues was involved in hydrogen
bonds in each predicted conformation and which residues of
LPS were targeted. The figures were constructed using PyMOL
(version 1.5.0.4; Schro¨dinger, LLC, New York).
In Vivo Experimental Models—Female BALB/c mice (6–8
weeks old, Charles River) were used in all experiments. Animal
experimental protocols were performed according to the
National/European Union Guidelines for the Care and Use of
Laboratory Animals in Research and approved by the Experi-
mental Animal Committee of the University of Seville and by
the Ethics Committee of the Spanish Council of Scientific
Research (file P09-CTS-4705).
To induce endotoxemia, mice were injected intraperitone-
ally with LPS (E. coli 055:B5, Sigma; 400 g/mouse). To induce
sepsis, the cecumof anesthetizedmice was ligated 5.0mm from
the cecal tip and punctured once with a 22-gauge needle. PBS
(controls), VIP, or the VIP derivatives (1 nmol in 200l of PBS)
were administered intraperitoneally at 1, 12, and 24h after cecal
ligation and puncture (CLP) or at 1 and 18 h after LPS injection.
The effective concentrations of the peptides used in the study
were chosen based on previous experiments performed in our
laboratory. Animals weremonitored daily for survival and clin-
ical signs. Sera and peritoneal fluid were collected by cardiac
puncture and peritoneal lavage, respectively, 6 and 24 h post-
CLP. The bacterial load was determined by dilution plating
onto trypticase soy agar with 5% sheep blood (BD Biosciences)
and cfu counting after overnight incubation. Peritoneal exu-
dates and sera were assayed for cytokine/chemokine contents
by using a specific sandwich ELISA (BD Pharmingen and Pep-
rotech). To evaluate histopathology, lungs were collected 24 h
after CLP, fixed in 10% buffered formalin phosphate, and pro-
cessed for paraffin embedding and sectioning (Leica). Cross-
sections (4-mthickness)were stainedwith hematoxylin/eosin
using standard techniques.
Colitis was induced as described previously (29). In brief,
mice were lightly anesthetized with halothane, and a 3.5F cath-
eter was inserted intrarectally 4 cm from the anus. 2,4,6-Trini-
trobenzene sulfonic acid (3mg; Sigma) dissolved in 50%ethanol
(to break the intestinal epithelial barrier) was administered into
the lumen via the catheter. Animals were treated intraperitone-
ally with vehicle or with 1 nmol/mouse VIP, VIP51, and
VIP51(6–30) at 1, 12, and 36 h after 2,4,6-trinitrobenzene sul-
fonic acid injection. Animals were monitored daily for the
appearance of diarrhea, loss of body weight, and survival.
Scores for stool consistency and rectal bleeding were assessed
according to procedures published previously (30).
To induce cutaneous leishmaniasis, mice were injected sub-
cutaneously in the left hind footpads with 104 L. major purified
metacyclic promastigotes isolated from stationary cultures by
negative selection with peanut agglutinin as described below.
Vehicle or peptides (1.5 nmol/mouse) were administered sub-
cutaneously in the infected footpad for 7 weeks (3 times/week)
starting 2 weeks postinfection. Disease progression was moni-
tored by measuring the inflammatory edema, and the area of
the cutaneous lesion of the infected footpad was measured by
using a digital caliper. Values obtained in the uninfected con-
tralateral footpad were used as a reference.
Parasite burdenwas determined 7weeks postinfection by the
presence of viable parasites in homogenates of the footpad,
spleen, and lymph nodes by using a limiting dilution assay (31).
Briefly, 12–24 serial 10-fold dilutions of the non-sedimented
fraction of the homogenates were seeded on flat-bottom
96-well plates and incubated in modified RPMI 1640 medium
supplemented with 20% FBS at 28 °C for 7–10 days to allow
transformation of amastigotes into promastigotes. We then
determined the number of positive wells (presence of motile
parasites) and negative wells using an inverted microscope.
Results were expressed as parasite burden (i.e. the highest dilu-
tion yielding growth of viable parasites). For histological analy-
sis, paws were fixed in 10% buffered formalin, decalcified in
Decalcifier I (Surgipath Europe Ltd.), embedded in paraffin,
sectioned, and stained with hematoxylin-eosin.
Purification of Metacyclic Parasites—Stationary phase
L. major promastigotes (108) were collected after 4 days in cul-
ture, washed with fresh supplemented M199 medium, and
incubatedwith 100g of peanut agglutinin (Vector Labs) for 15
min at room temperature. Cells were separated by centrifuga-
tion (500  g, 10 min, 4 °C), and non-agglutinated metacyclic
promastigotes were collected from the supernatant and diluted
at 2.5 105 cells/ml in PBS supplemented with 0.5 mM MgCl2
and 1 mM CaCl2.
Assessment of T Cell Response—Single-cell suspensions (106
cells/ml) from draining lymph nodes isolated after 5 weeks
postinfection were incubated in complete RPMI medium and
restimulated with 2.5 g/ml concanavalin A for 48 h (for cyto-
kine determination) or for 72 h (for proliferative response).
Cytokine and chemokine contents in culture supernatantswere
determined by specific sandwich ELISA. Cell proliferation was
evaluated by the addition of 2.5 Ci/ml [3H]thymidine during
the last 8 h of culture and determination of cpm in aMicrobeta
counter 1450 (Wallac).
Statistical Analysis—All data are expressed as the mean 
S.E. Statistical analysis was carried out using Student’s t test or
one-way analysis of variance followed by Bonferroni’s post-test
to evaluate differences between groups. We assumed signifi-
cance at p 0.05.
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RESULTS
The VIP Derivatives Showed Higher Bactericidal Activity
than Native VIP—We first investigated the bactericidal activity
of the two synthesized derivatives of VIP, VIP51 and the frag-
ment VIP51(6–30). The chemical modifications achieved to
increase the stability of native VIP resulted in peptides with
higher positive charge and hydrophobic nature thanVIP (Table
1 and supplemental Fig. S1). VIP51 and VIP51(6–30) showed
potent antimicrobial activities against a wide panel of Gram-
negative and Gram-positive bacteria, including pathogenic
strains such as P. aeruginosa, E. aerogenes, E. faecalis, and
E. coli expressing complete, O-antigen-containing LPS (Fig. 1).
In general, bothVIP derivatives showedEC50 values below1M
(Table 2). As expected, the VIP derivatives weremore potent as
antibacterial peptides than VIP (Fig. 1).Whereas the VIP deriv-
atives showed complete bactericidal effect (100% mortality)
against P. pseudoalcaligenes, P. aeruginosa, and E. coli O-anti-
gen, VIP treatment never reached more than 70% bacterial
death (Fig. 1). Moreover, the VIP derivatives showed lower
EC50 values than VIP for all of the bacteria strains assayed
(Table 2). Interestingly, the VIP derivatives, but not VIP, were
able to efficiently kill Gram-positive bacteria (Fig. 1B and Table
2). The lack of recovery of bacterial viability after removal of the
VIP derivatives indicated that these peptides were bactericidal
as opposed to bacteriostatic.
To confirm the selectivity of these antimicrobial peptides for
microbes and to confirm that they are not toxic formammalian
cells, we performed toxicity and hemolytic assays. Neither
VIP51 nor VIP51(6–30) affected the viability of mouse primary
macrophages and splenocytes (97 3 and 98 1% cell survival,
respectively) or lysed erythrocytes (2.5  0.5 and 3.1  0.1%
hemolysis for VIP51 and VIP51(6–30), respectively) at the
highest concentration assayed as antimicrobials in this study.
The VIP Derivatives Altered the Integrity of the Bacterial
Plasma Membrane—Most of the cationic antimicrobial pep-
tides target bacteria through electrostatic interactions with the
microbial membrane. This generally results in formation of
transmembrane pores and loss of membrane integrity that
causes cell death. In this study, we used E. coli to investigate the
potential mechanisms involved in the bactericidal effect of
VIP51 and VIP51(6–30) because of the higher susceptibility of
Gram-negative bacteria to both peptides and the accessibility to
mutants of this strain and because Gram-negative bacteria are
the major cause of sepsis (an experimental model later used in
our study). We used two complementary approaches to inves-
tigate bactericidal effect of the two VIP derivatives. First, we
monitored membrane depolarization by using the bisoxonol
dye, a lipophilic anion that enters into membranes only if their
potential has collapsed. Second, we tested the access of the vital
dye SYTOX Green, which requires large size lesions in the
membrane to enter into the cell, being precluded in intact cells.
We found that bacteria cultured with the VIP derivatives
showed significant increases in the uptake of bisoxonol (Fig. 2A,
left) and SYTOX (Fig. 2A, right). Interestingly, native VIP
increased the depolarization, but not the permeabilization, of
bacterial membrane (Fig. 2A). As a consequence of this effect,
we observed a significant depletion on ATP levels in bacteria
treated with the VIP derivatives (82.5% for VIP51, 78.6% for
VIP51(6–30); Fig. 2B). However, VIP caused a marginal ATP
depletion (28.2%; Fig. 2B). These results suggest that only the
VIP derivatives affect simultaneously the potential and integ-
rity of the bacterial membrane. This could explain the higher
antimicrobial activity of the VIP derivatives compared with
VIP.
To further characterize the bactericidal activity of the VIP
derivatives, we incubated bacteria with FITC-labeled VIP51/
VIP51(6–30). We observed that both peptides rapidly targeted
the whole bacterial surface and exerted an agglutinating effect
that resulted in multiple bacteria aggregates in the culture (Fig.
2C). Moreover, ultrastructural images of bacteria treated with
VIP51 showed a complete disorganization of the plasma mem-
brane and the presence of visible pores throughout the surface,
multiple intracellular vacuoles, and cytoplasmic content sur-
rounding bacteria (Fig. 2D). These cellular changes were even
more drastic in VIP51(6–30)-treated bacteria, which appeared
completely disintegrated in the samples (data not shown).
Specific Factors Influencing Antibacterial Activity of VIP51
andVIP51(6–30)—The bactericidal activities of the antimicro-
bial peptides are strongly influenced by the ionic strength and
pH of themedium.Whereas a previous study reported that VIP
almost completely loses its antibacterial effect against E. coli at
physiological concentrations of 150 mM NaCl (32), we found
that both VIP derivatives fully kept their bactericidal effects
(E. coli survival rate, 6.0  1.2% for VIP51 and 0.9  0.5% for
VIP51(6–30)) at this concentration of NaCl. Furthermore, the
presence of high salt concentrations (180 mMNaCl) attenuates
the activity of VIP51 slightly, but not that of VIP51(6–30),
against both the Gram-negative E. coli and the Gram-positive
E. faecalis (Fig. 3A), supporting the functional relevance of
these peptides in physiological fluids. However, an increase of
the ionic strength of the medium (with 50 mM MgCl2) signifi-
cantly abolished the bactericidal activity of the VIP derivatives
TABLE 1
Sequence and structural properties of VIP and the VIP derivatives
Numbers correspond to the positions of the amino acids in the sequence of each peptide. Cationic residues are shaded, anionic residues are in italic type, and hydrophobic
residues are underlined.
a Grand average of hydropathicity. Negative and positive GRAVY values correspond to hydrophilic and hydrophobic peptides, respectively. Net charges and gravy indexes
were calculated by using the Bioinformatics Resource Portal and Antimicrobial Peptide Predictor database.
b Percentage of -helix in the structure.
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in both strains (Fig. 3A). These results indicate that electrostatic
interactions between the VIP derivatives and bacterial targets
might play a critical role in their antibacterial activity.
On the other hand, we demonstrated that the antimicrobial
activities of VIP and its derivatives in Gram-negative but not in
Gram-positive bacteria depend on the pH of the medium (Fig.
3B). Interestingly, the three peptides gained and lost effective-
ness killing E. coli at basic and acidic pH conditions, respec-
tively (Fig. 3B). Whereas the three peptides are positively
charged at pH values between 5.0 and 9.0, the net charge of
bacterial membrane is more negative when the pH of the
medium raises. Therefore, a basic environment could favor
stronger interactions of the bacteria with the more cationic
VIP51 and VIP51(6–30).
Another importantmodulator of the antimicrobial activity is
LPS, the main outer membrane component of Gram-negative
bacteria (33, 34). In order to study the role of LPS in the anti-
microbial effect of the VIP derivatives, we tested their action in
five mutant strains derived from E. coli K-12 D21, which are
differentially defective in various components of the LPS mol-
ecule (Fig. 4A). Our data showed that the antibacterial activity
of VIP and its derivatives against the mutants expressing the
truncated forms of LPS did not significantly change in compar-
ison with that shown by the wild type D21“Ra” strain, with the
FIGURE 1. Bactericidal activity of VIP and the VIP derivatives. Cell viability of non-pathogenic (E. coli Top 10, P. pseudoalcaligenes) and pathogenic (E. coli
expressing complete O-antigen-containing LPS, P. aeruginosa, E. aerogenes) Gram-negative bacteria (A) and non-pathogenic (M. luteus) and pathogenic
(E. faecalis) Gram-positive bacteria (B) incubatedwith various concentrations of native VIP, VIP51, or VIP51(6–30) for 3 h. Data are expressed as the percentage
of survival (by counting cfu) relative to untreated bacteria. Themean S.E. (error bars) (n 4, each performed in duplicate) is shown. *, p 0.05; **, p 0.001
versus untreated bacteria; #, p 0.05 versus VIP-treated bacteria (dose curve).
TABLE 2
Bactericidal activity of VIP, VIP51, and VIP51(6–30)
Mean S.E. of four independent experiments is shown.
Bacteria tested
EC50
VIP VIP51 VIP51(6–30)
M
Gram-negative
E. coli (Top10) 1.50 0.53 0.66 0.09 0.32 0.03
E. coli 0.42 0.20 0.16 0.01 0.10 0.03
P. aeruginosa 0.70 0.34 0.21 0.10 0.20 0.02
E. aerogenes 20 2.00 0.23 0.59 0.52
P. pseudoalcaligenes 2.66 0.95 0.01 0.00 0.01 0.00
Gram-positive
S. mutans 19.06 0.76 15.08 0.24 2.92 1.72
M. luteus 20 0.03 0.01 0.15 0.04
E. faecalis 20 1.17 0.02 1.01 0.01
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exception of the mutant D21e7“Rc” that lacks the outer net-
work of residues of -D-glucose (GLC), which significantly
reversed the activity of VIP51(6–30) (p  0.01 by analysis of
variance; Fig. 4B). This suggests that, although it could partici-
pate, the oligosaccharide core of LPS is not essential for the
bactericidal activity of VIP and the VIP derivatives against
E. coli. In fact, the three peptides showed the best EC50 values
against the D21f2“Rd” strain, which only retains the portion of
the molecule containing Lipid A and 3-deoxy-D-manno-octu-
losonic acid (KDO) groups (Fig. 4B).
To investigate the potential molecular interactions of VIP
analogues with LPS, we performed a series of docking simula-
tions by using the LPS derived from E. coli K-12 D21 strain as a
model. We observed that less than 25% of the hydrogen bonds
established between VIP or the VIP derivatives and LPS were
made with the outer network of residues of -D-glucose and
-D-galactose, whereas most of the interactions (67–72%)
occurred with the polar groups of Lipid A and KDO residues of
LPS (supplemental Tables S1–S3). These findings were con-
firmed by docking simulations of the peptides with the trun-
cated LPS containing only Lipid A and KDO (Tables S4–S6).
Interestingly, almost all the amino acids of VIP and its deriva-
tives that established hydrogen bonds with LPS are located
in the middle portion of the peptide, a domain that concen-
trates the majority of the cationic residues (Tables S1–S3).
Moreover, the substitution K15R made in VIP51(6–30)
increased its interaction with -D-galactose residues of LPS
(supplemental Table S3). This could be relevant to explain the
attenuation in the killing activity of VIP(6–30) against the
D21e7“Rc” mutant (Fig. 4B).
The VIP Derivatives Protected against Severe Sepsis by Induc-
ing Bacterial Clearance—Herein, we aimed to investigate the
potential therapeutic effect ofVIP51 andVIP51(6–30) in a clin-
ically relevant experimental model of polymicrobial sepsis
induced in mice by CLP.We found that after cecal perforation,
all untreated animals died (Fig. 5A) as a consequence of a focal
infection (peritoneum) that subsequently became systemic
(blood) (Fig. 5B), which induced the secretion of cytotoxic
FIGURE 2. The VIP derivatives bind to the bacterial surface and disrupt the membrane integrity. A, the potential (left) and integrity (right) of plasma
membrane of E. coli Top 10 culturedwith PBS (control), VIP, or the VIP derivatives (each at 10M for 1 h) were determined by changes in bisoxonol and SYTOX
Green fluorescence, respectively. Results are expressed as -fold change in depolarization or permeabilization, (F/Fm)/(Fo/Fm), where F is the fluorescence of
peptide-treated bacteria, Fo is the fluorescence of untreated bacteria, and Fm is the maximal fluorescence achieved by heated E. coli. B, levels of bacterial ATP
(expressed as luminescence units) in E. coli Top 10 treated with PBS (control), VIP, or the VIP derivatives (each at 10 M for 1 h). C, binding of FITC-labeled VIP
derivatives to E. coli Top 10. Bacteria were DAPI-counterstained (blue corresponds to nucleic acids). Insets, Normarski images. Scale bar, 2m.D, ultrastructural
analysis of E. coli incubated with PBS (controls) or with VIP51 (5M) for the indicated times. Arrows point to intracytoplasmic vacuoles and sites of membrane
damage. Scale bar, 0.5 m. Images are representative of three independent experiments in which more than 95% of the cells displayed this pattern. In A and
B, the mean S.E. (error bars) (n 4, each performed in duplicate) is shown. *, p 0.05; **p 0.001 versus untreated bacteria (control).
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and inflammatory factors by immune cells (Fig. 5C). These
responses caused inflammatory infiltration; tissue damage and
disseminated coagulation in target organs, such as lung (Fig.
5D); and the subsequent multiorgan failure characteristic for
sepsis. The therapeutic efficacy of VIP on lethal sepsis by down-
regulating inflammatory mediators was reported previously
(35). As expected, VIP treatment reduced mortality, bacterial
loads, and inflammatory mediators in septic animals (Fig. 5,
A–C). Similarly, the administration of the VIP derivatives into
the peritoneum of septic animals significantly increased the
survival (Fig. 5A) and drastically reduced the local and systemic
bacterial loads (Fig. 5B). Subsequently, treatment with the VIP
derivatives reduced inflammatory mediators and the histo-
pathologic alterations associated with sepsis (Fig. 5, C and D).
These results suggested that the protective effect exerted by the
VIP analogues might be primarily mediated through a local
bactericidal effect. Indeed, it is widely known that persistence of
the local bacterial infection plays a critical role in the severity
and progression of sepsis. To support this hypothesis, we per-
formed additional experiments to separate the direct antimi-
crobial activity of the VIP derivatives from their potential anti-
inflammatory action. First, we analyzed the direct antibacterial
activity of VIP and the VIP analogues against four different
Gram-negative strains isolated from the peritoneal fluid ofmice
with CLP-induced sepsis. Only the VIP derivatives were effec-
tive against these pathogenic bacterial strains (Table 3). Sec-
ond, we compared the effect of VIP51 and VIP51(6–30) in a
severe form of septic shock induced by LPS, which causes exac-
erbated systemic inflammatory responses and multiorgan fail-
ure in the absence of bacterial infection. Also, we investigated
the effect of the VIP derivatives in a model of chemically
induced colitis characterized by uncontrolled colonic inflam-
mation. As demonstrated previously (36, 37), treatment with
native VIP was protective in both inflammatory disorders (Fig.
6). However, only VIP51, and not VIP51(6–30), reduced mor-
tality caused by the bacterial endotoxin (Fig. 6A) and improved
clinical evolution of colitis caused by bowel inflammation in the
absence of infection (Fig. 6B). Together, these results indicate a
dual role for VIP51 that combines the equipotent immuno-
modulatory role of VIP with an improved stability and higher
antimicrobial activity. However, VIP51(6–30) does not share
with VIP its capacity to regulate host immune responses in
inflammatory conditions, although it protected efficiently from
sepsis by neutralizing living bacteria.
The VIP Derivatives Killed Promastigotes of Leishmania by
Inducing the Formation of Pores in the PlasmaMembrane—We
next investigatedwhether the antimicrobial effect of VIP51 and
VIP51(6–30) could be extended to other pathogens, such as
tropical trypanosomatid parasites. Among them, Leishmania
represents a global health problem with ineffective drug treat-
ments. This is an obligate intracellular organism with a dige-
netic life cycle alternating between the flagellated, extracellular
promastigote form in the digestive tract of the sandfly vectors
and the aflagellated amastigote form that lives inside mononu-
clear phagocytic cells and causes the disease symptoms in
mammals. This protozoan parasite is one of the most used
models to assay antiparasitic strategies. Importantly, Leishma-
nia species have a highly negative glycocalix that makes them
attractive targets for antimicrobial peptides (38).
Therefore, we assayed the antiparasitic activity of the three
peptides against different species of Leishmania. The two VIP
derivatives, but not VIP, significantly reduced the viability of
promastigote forms of L. major, which causes cutaneous leish-
maniasis (Fig. 7A and Table 4). With the exception of the effect
FIGURE3.Determinants influencing theantibacterial effect of theVIPderivatives.A, effect of the ionic strengthof themediumon the activity of native VIP
and the VIP derivatives against E. coli and E. faecalis. Bacteria were incubatedwith VIP, VIP51, and VIP51(6–30) (each at 5M) in the absence or presence of 180
mMNaCl or 50mMMgCl2 for 3 h. *, p 0.05; **, p 0.001 versuspeptide-treated bacteria; #, p 0.05 versus untreated bacteria at each condition. B, effect of pH
of themediumon the antimicrobial activity of VIP and the VIP derivatives (5M, 3 h of culture) against E. coli and E. faecalis.**, p 0.001 versus controls at each
pH; #,p0.05 versuspeptide-treatedbacteria at pH7.0. In bothpanels, survivalwasdeterminedasdescribed in the legend to Fig. 1. Themean S.E. (error bars)
(n 3, each performed in duplicate) is shown.
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of VIP51(6–30) in L. tropica, the other species of the parasite
responsible of visceral manifestations of leishmaniasis were resis-
tant to the VIP derivatives (Table 4). Therefore, we selected
L.major to further characterize the mechanisms involved in the
leishmanicidal actions of theVIP derivatives. Similar to our obser-
vation in bacteria, VIP51 and VIP51(6–30) bound in less than 5
min to the whole surface of the parasite, induced a complete dis-
organization of the parasite structure (reflected by the acquisition
of a roundedmorphology), and caused leakage of the cellular con-
tent (Fig. 7B). Moreover, incubation of L.major promastigotes
with VIP51 or VIP51(6–30) resulted in a rapid dissipation of the
membrane potential and an increase in the influx of SYTOX
Green (Fig. 7C).These findings suggest that theVIPderivativeskill
L.major by disrupting the plasmamembrane of the promastigote
through the formationof large size lesions.Themembranedisrup-
tion caused by VIP51 and VIP51(6–30) led to a collapse of the
bioenergetic metabolism of the parasite monitored by a sustained
decrease in intracellular ATP levels (Fig. 7D). To study how these
effects translated into morphological changes, we analyzed the
peptide-treated parasites by transmission electron microscopy.
Treatment with VIP51 induced the formation of pores in the
plasmamembrane, a complete disruptionof cell integrity, and loss
of cytoplasmic material that was found in the extracellular
medium (Fig. 7E).
Next, we evaluated determinants influencing the antipara-
sitic activity of the VIP analogues. We observed that the leish-
manicidal effect of the VIP derivatives strongly depended on
the ionic strength of the medium because it was completely
abolished in the presence of high salt concentrations (Fig. 8A).
Moreover, the pH of themedium influenced the killing effect of
the VIP derivatives. Whereas the leishmanicidal activities of
both peptides increased at basic conditions, VIP51 completely
lost its killing effect at the acidic pH (which is similar to the pH
found inside of the parasitophorous vacuole) (Fig. 8B). Interest-
FIGURE 4. Antimicrobial activity against E. colimutants deficient in LPS synthesis. A, scheme of LPS from E. coli K-12 D21 chemotype. GLC, -D-glucose;
GLA, alpha-D-galactose; GMH, L-glycero-D-mannoheptopyranose; NAG, N-acetylgalactosamine; DPO, diphosphate; PA1, 2-amino-2-deoxy--D-glucopyranose;
GCN, D-glucosamine;OM, outermembrane. B, antimicrobial activity of VIP, VIP51, and VIP51(6–30) (added at 5M for 3 h) againstmid-log phase growth E. coli
chemotypes (D21Ra and defective strains D21e19, D21e7, D21f1, and D21f2). Cell viability was determined with the BacTiterGlo kit and expressed as the
percentageof survival versusuntreated control bacteria.Numbers inparenthesis showEC50 for eachpeptide. ThemeanS.E. (error bars) (n4, eachperformed
in duplicate) is shown. *,p 0.05; **,p 0.001 versusuntreatedbacteria; #,p 0.05 versusVIP-treatedbacteria; &,p 0.05 versusVIP51(6–30)-treatedbacteria
at the indicated dose.
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ingly, VIP51(6–30) still maintained (over 50% of) the leish-
manicidal activity at this pH 5.0 (Fig. 8B).
To investigate potential targets for the VIP derivatives in the
parasite, we considered the LPG, a major anionic component of
the glycocalix of Leishmania promastigotes, as a potential target.
LPG structurally contains repeated PG units (Gal-Man-P)
anchoredbyaglycancore to aphosphatidylinositol anchor (39). In
addition, both promastigotes and infecting amastigotes contain
moderate levels of proteophosphoglycan, a mucin-like protein
alsomodified by the PG repeats. To determine the involvement of
LPG and proteophosphoglycan in the leishmanicidal activity of
the VIP derivatives, we used an inducible system of LPG and an
lpg2/mutant (24) that lacks aGolgi GDP-mannose transporter
required for PG synthesis (40). We observed that the absence of
LPG and proteophosphoglycan significantly impaired the leish-
manicidal activity of VIP51 (Fig. 8C), suggesting that both anionic
molecules are essential for its action in L.major.
Therapeutic Activity of the VIP Derivatives in Experimental
Cutaneous Leishmaniasis—Finally, we evaluated the capacity
of the VIP derivatives to protect BALB/c mice against L. major
FIGURE 5. The VIP derivatives improve survival and bacterial clearance in sepsis. A, survival of mice subjected to sepsis by CLP and treated with vehicle
(control) or with VIP, VIP51, and VIP51(6–30) (n 20mice/group). B and C, bacterial load (B, n 10mice/group) and cytokine contents (C, n 5mice/group)
were determined in sera and peritoneal fluids isolated 24 h after sepsis induction. The mean S.E. (error bars) (n 4, each performed in duplicate) is shown.
n.d, not detectable. *, p  0.05; **, p  0.001 versus untreated control mice. D, histological sections of lungs isolated 24 h after CLP induction. Images are
representative of 10 mice/group. Scale bar, 100 m.
TABLE 3
Bactericidal activity of VIP, VIP51, and VIP51(6–30) against peritoneal
bacterial isolated from septic mice
Mean S.E. of four independent experiments is shown.
Bacteria tested
(Gram-negative)
EC50
VIP VIP51 VIP51(6–30)
M
B1 20 0.41 0.07 1.25 0.36
B2 20 0.52 0.14 0.28 0.05
B3 20 0.59 0.06 0.16 0.07
B4 20 0.04 0.01 0.15 0.08
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infection. Treatmentwith native VIPwas included as a negative
control because it did not show leishmanicidal activity. Mice
infected in the hind footpad with purified metacyclic promas-
tigotes of L. major developed marked and progressive inflam-
matory edema and cutaneous lesions around the site of injec-
tion (Fig. 9A). Analysis of histopathology of the cutaneous
lesions showed extended areas of necrosis and ulceration in
epidermis as well as erosion and destruction of cartilage and
bone caused by a severe granulomatous inflammation as a con-
sequence of the accumulation of parasite-infected macro-
phages in the dermis (Fig. 9B). Although the injection of the
three peptides diminished paw swelling and lesion size, only the
treatment with VIP51(6–30) significantly controlled the clini-
cal manifestations and progression of this disease (Fig. 9A) and
abolished the histopathologic signs in the infected footpads
(Fig. 9B). The protective effect of VIP51(6–30) in cutaneous
leishmaniasis correlated with a striking decrease in the number
of living parasites in cutaneous lesions (Fig. 9C). It is notewor-
thy that treatment with VIP51(6–30) also prevented the sys-
temic dissemination of this pathogen to immune and visceral
organs (Fig. 9C). Moreover, treatment with VIP51(6–30) nor-
malized the exacerbated immune response observed in the
infected animals (Fig. 10), probably as a consequence of a
reduced parasite load. Although treatment with VIP51 limited
the presence of parasites in target organs, such as liver and
draining lymph nodes (Fig. 9C), this was not enough to signifi-
cantly ameliorate the clinical course of the disease (Fig. 9A).
DISCUSSION
With microbial drug resistance becoming a global public
health problem, it is imperative to develop new anti-infective
strategies. In this sense, nature has chosen a different concept
for the evolution of the innate host defense, favoring the
appearance of compounds able to modulate many biological
functions that simultaneously affect the host and the patho-
gens. Thus, neuropeptides with antimicrobial properties could
represent one of the most promising future strategies for com-
bating infections. However, the potential therapeutic possibili-
ties of these peptides are usually limited by some drawbacks
concerning metabolic stability, bioavailability, immunogenic-
ity, routes of administration, and production cost that must be
overcome (41). Therefore, research has been focused on avoid-
ing these disadvantages and improving the therapeutic efficacy
of thesemolecules.Our study supports the view considering the
design principles of neuropeptides as primitive and effective
antimicrobial molecules to develop novel drugs. Here, we dem-
onstrate that VIP51, a metabolic stable analogue of VIP gener-
ated by substitutions/additions of critical residues, and an
N-terminal truncated derivative of VIP51 (VIP51(6–30)) were
more potent than native VIP as antimicrobial peptides against
various non-pathogenic and pathogenic Gram-positive and
Gram-negative bacteria. Moreover, both VIP derivatives, but
not VIP, were able to kill tropical protozoa parasites from the
genus Leishmania.
Besides the increase in their stability, the chemical changes
made in VIP51 and VIP51(6–30) increased the cationic charge
and hydrophobicity of the molecule and improved their fea-
tures as antimicrobial peptides. Moreover, these modifications
produced relevant changes at the structural level. Thus, both
VIP derivatives adopted a clear amphipathic structure consist-
ing of a highly cationic N-terminal middle domain and a C-ter-
minal domain enriched in hydrophobic residues. This structure
could explain the potent antimicrobial activity observed for
VIP51 andVIP51(6–30) in comparisonwith the native VIP and
their selectivity for pathogens versus mammalian cells. Both
VIP derivatives are able to recognize and interact with anionic
residues exposed in the outer surface of bacteria and parasites
but not with the neutral membrane of mammalian cells. After
their binding to the surface of the pathogen, VIP51 and
VIP51(6–30) induced the depolarization of the membrane
through the formation of disrupting pores, which led to a col-
lapse of the intracellular ATP levels and the subsequent death
of the pathogens. In general, the mechanism(s) through which
antimicrobial peptides may permeabilize and traverse micro-
bial membranes are not entirely clear and probably vary for
different peptides. Our data suggest that a translocation mech-
anism termed “self-promoted uptake” described for other anti-
microbial peptides against Gram-negative bacteria (54) could
fit with the way of action of the VIP derivatives. According to
this theory, theVIPderivativeswould initially bind to the LPSof
FIGURE 6.Modulation of the host immune response in endotoxemia and
inflammatory bowel disease. A, survival of mice subjected to LPS-induced
endotoxemia and treated with PBS (control) or with VIP, VIP51, and VIP51(6–
30). n  12–16 mice/group, from three independent experiments. B, body
weight loss, colitis scores, and survival of mice subjected to 2,4,6-trinitroben-
zene sulfonic acid-induced colitis and treated with PBS (control) or with VIP,
VIP51, and VIP51(6–30). n  12–16 mice/group, from three independent
experiments. **, p 0.001 versus untreated control mice. Error bars, S.E.
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the outer membrane, causing displacement of divalent cations
that bridge and neutralize LPS. This would generate destabi-
lized outer membrane areas through which peptides could
translocate. After the peptide adsorption to the outer leaflet of
membrane and after acquiring a certain concentration, the pep-
tides could insert into the membrane surface through their
hydrophobic domain. This could cause a chemical potential
imbalance across the bilayer and result in the translocation of
the peptides to the inner membrane. Then peptides could
aggregate and insert deeper into the hydrophobic membrane
core, facilitating membrane rupture and pore formation.
Besides the disruption of the membrane integrity through the
formation of pores or other aggregated structures, changes in
the influx/release of ions through ion channelsmay cause depo-
larization of cell membranes. Interestingly, the native VIP only
causes depolarization and not disruption of the bacterial mem-
brane, leading to a bacteriostatic action more than to a bacteri-
FIGURE 7. The VIP derivatives induce the formation of disrupting membrane pores in L. major promastigotes. A, cell viability of L. major Friedlin clone V1
incubatedwithmedium(control)orwithvariousconcentrationsofVIPandtheVIPderivativesdeterminedbyreductionofAlamarBlueandexpressedasapercentage
of untreated control samples. B, binding of the FITC-labeled VIP derivatives to L. majorpromastigotes (bottompanels). Top panels, Normarski images.Arrowspoint to
sites of plasmamembrane damage. Bars, 4m. C, variation in plasmamembrane potential (top) and integrity (bottom) of parasites culturedwithmedium (control),
VIP51, or VIP51(6–30). Data are expressed as a percentage of fluorescence intensity relative to that achieved by maximal depolarization or permeabilization. D,
changes in ATP levels (expressed as luminescence units) in L. majorpromastigotes culturedwithmedium (control), VIP51, or VIP51(6–30). Parasites incubated in the
absenceofglucosewereusedasnegativecontrols.E, ultrastructural analysisof thecell damagecausedbyVIP51 inL. major. Thearrowspoint tomembranebreakages
(at 1 h) and depletion of electron-dense cytoplasmic material, severe cellular damage, and apparent leakage of the cytoplasmic content (at 4 h). Bars, 1 m. The
mean S.E. (error bars) (n 3, each performed in duplicate) is shown. *, p 0.05; **, p 0.001 versus untreated parasites; ##, p 0.001 versus VIP-treated parasites.
TABLE 4
Antiparasitic activity of VIP, VIP51, and VIP51(6–30) against Leishma-
nia sp.
Mean S.E. of four independent experiments is shown.
Parasite
EC50
VIP VIP51 VIP51(6–30)
M
L. major 24 3.39 0.24 1.74 0.45
L. mexicana 24 24 24
L. donovani 24 24 24
L. tropica 24 24 16.31 0.18
L. infantum 24 24 24
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cidal effect. Indeed, depolarization of the cytoplasmic mem-
brane is not, per se, a lethal event in bacteria (55). In this sense,
we cannot discard the involvement of modifications of ion
channel activity by native VIP. Regarding this, large scale
genome analyses showed that prokaryotes express ion channels
belonging to molecular families expressed in neurons (42), and
VIP modulates different ion channels in neurons, in the range
of high concentrations used in our study (43).
Because LPS is a highly anionic molecule and represents up
to 50% of the outer membrane of Gram-negative bacteria, it
emerges as a potential target for the VIP derivatives. Our data
indicate that, although it could facilitate the antibacterial activ-
ity of the VIP derivatives, the oligosaccharide core of LPS is not
essential. In fact, docking simulations supported the capacity of
VIP, VIP51, and VIP51(6–30) to bind to LPS. However, the
three peptides interacted minimally with the outer network of
carbohydrates of LPS and established most of the hydrogen
bonds with other inner anionic moieties of LPS, such as KDO
and various components of Lipid A, in close proximity with the
bacterial membrane surface. Most of the amino acid modifica-
tions made in the derivatives seem to have roles in establishing
new hydrogen bonds with an LPS molecule. Moreover, the fact
that the substitutions N24A and S25A at the C-terminal region
of the native peptide generated a strong hydrophobic domain in
the two VIP derivatives could be even more critical in the for-
mation of disrupting pores in the bacterial membrane by VIP51
andVIP51(6–30) but not byVIP, which only causedmembrane
depolarization. Furthermore, the addition of the motif GRR at
the C terminus in the VIP derivatives increased the proportion
of -helix in the molecule and changed the distribution of the
amino acids in the molecule, favoring the orientation of the
cationic residues on the same side (supplemental Fig. S1),
which could improve their binding capacity to LPS.
Interestingly, VIP and its derivatives showed the strongest
antimicrobial activities against pathogenic E. coli strains that
express complete O-antigen-containing LPS. This suggests
that, far from being a permeability barrier and a cause of resis-
tance, as occurs with other antimicrobial peptides (33), the ani-
onic nature of the O-antigen and oligosaccharide core could
facilitate the recruitment of theVIP derivatives to the surface of
bacteria and allow a critical peptide concentration to form
pores. This finding could be also related to the capacity of the
two derivatives to induce bacterial aggregation, which repre-
sents an ancient mechanism of defense to neutralize pathogens
(56). Some peptides, like the eosinophil cationic protein,
decrease their antimicrobial activity with a progressively trun-
cated LPS core (57), a fact that is related to the involvement of a
complete LPS in their agglutinating activity.
On the other hand, whereas nativeVIP failed to kill any of the
Gram-positive bacteria strains tested, both derivatives showed
potent antimicrobial activity against non-pathogenic S. mutans
and M. luteus and pathogenic E. faecalis, a strain that is nor-
mally resistant to many cationic peptides. The differential bac-
tericidal effects found between the VIP derivatives and native
FIGURE 8. Determinants influencing leishmanicidal activity of the VIP derivatives. A, effect of the ionic strength of the medium on the activity of VIP
analogues against L. major. Survival of parasites incubatedwith VIP51 and VIP51(6–30) (12M) in the absence or presence of 180mMNaCl or 50mMMgCl2 for
4 h. **, p 0.001. B, effect of pH of the medium on the antiparasitic effect of the VIP derivatives (12 M, 4 h of culture) against L. major. **, p 0.001 versus
controls at eachpH; #,p0.05 versuspeptide-treatedparasites at pH7.0.C, VIP51 requires the interactionwith LPGandPGof theparasite surface to kill L. major
promastigotes. The effect of VIP51 on the cell viability of the mutant strain of L. major glf/Kidd GLF-1F lacking LPG (glf/Kidd GLF-1F L. major Friedlin V1
parasites treated with FK506 that induces LPG expression were used as the WT strain for comparison) or the L. major lpg2
/ and lpg2/mutants lacking PG
(LV39wtwas used as theWT strain for comparison) is shown. Survival was expressed as a percentage of cell viability of their correspondingWT strains. Data are
the mean S.E. (error bars) of three independent experiments, each performed in duplicate. *, p 0.05; **, p 0.001 versus untreated parasites; #, p 0.01;
##, p 0.001 versusWT treated parasites.
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VIP could be due to the higher net positive charge and hydro-
phobicity of the former because both characteristics seem to be
critical in the susceptibility of some Gram-positive bacteria,
such as S. mutans, tomany antimicrobial peptides (44). Because
VIP51(6–30) has a higher positive charge and -helix percent-
age than VIP51, VIP51(6–30) could interact better with
S. mutans and cause its death at lower peptide concentrations.
The killing effect against Gram-positive bacteria is especially
relevant from a therapeutic point of view because these bacteria
have a thick cell wall and develop sophisticated resistance
mechanisms such as the absence of uncharged lipids (45). How-
ever, the mechanisms involved in this effect by the VIP deriva-
tives are still unknown.
It is noteworthy that the treatment with either of the twoVIP
derivatives significantly increased the survival in an experimen-
tal model of polymicrobial sepsis, a major cause of mortality
and morbidity that remains difficult to treat. Our hypothesis is
that VIP51 protects against sepsis through two non-redundant
actions. VIP51may act as an agonist of VIP receptors expressed
in immune cells, and like VIP (46), it would regulate the inflam-
matory immune response of the host by reducing a plethora of
inflammatorymediators that cause themultiorgan failure char-
acteristic of sepsis. At the same time, VIP51 may exert a potent
antimicrobial activity by directly killing pathogenic bacteria.
However, VIP51(6–30) seems to prevent mortality caused by
sepsis mainly by reducing the bacterial load. This effect could
be enough to reduce the later storm of inflammatory and cyto-
toxic factors. Because VIP51(6–30) lacks the N-terminal resi-
dues that are critical to activate VIP receptors, we assume that
VIP51(6–30) is unable to directly regulate the inflammatory
FIGURE 9. In vivo effects in experimental cutaneous leishmaniasis. A, inflammatory edema (top) and lesion size (bottom) in footpads of mice infected with
metacyclic L. major and treated locally with saline (control), VIP, VIP51, or VIP51(6–30). Contralateral uninfected footpads were used as basal controls. Pictures
show representative images of footpad inflammation and necrotic cutaneous lesions at 7 weeks postinfection. Data are the mean S.E. (error bars) of one
representative experiment of five (n 10 mice/group). B, histopathologic analysis of the footpad lesions of uninfected and infected mice treated with saline
(control) or peptides. Thearrowspoint toparasites inside andoutsideof infectedmacrophages. Left scale bars, 100m; right scale bars, 5m.Magnified images
show amastigote forms of Leishmania (stars) lining the walls of the vacuoles following a typical arrangement. They can be distinguished as the darkly stained
nucleus and kinetoplast closely associated. Images are representative of 5 mice/group, three independent experiments. C, parasite loads in footpads, liver,
spleen, and draining lymph nodes in infectedmice treatedwith saline (control), VIP, or the VIP derivatives (at 7 weeks postinfection). Data are themean S.E.
of one representative experiment of three (n 5 mice/group). *, p 0.05; **, p 0.001 versus untreated infected mice.
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response. In fact, we present evidence that VIP51(6–30) failed
to protect against pathogen-free inflammatory disorders, in
which VIP and VIP51 were effective. Relevant for a therapeutic
application was the fact that VIP51 and VIP51(6–30) resisted
high salt concentrations (up to 180 mMNaCl), contrary to VIP,
which completely lost its antimicrobial capacity in a physiolog-
ical saline environment (32).
In the case of the parasiteLeishmania, the cytolytic activity of
the two VIP derivatives consisted of their initial interaction
with specific components of the parasite surface, followed by
the damage of the plasma membrane through the induction of
large-sized lesions. This is a death mechanism shared with
other leishmanicidal peptides (47). Importantly, we identified
specific targets for the VIP derivatives on the parasite surface.
The plasma membrane of the promastigote stage possesses a
thick anionic glycocalix made up mostly of LPG (48) and the
externalGPI-anchoredmetalloproteinase gp63 (49). Both com-
ponents are involved in the interaction with and partial resis-
tance to antimicrobial peptides (50). Using differentmutants of
L. major (24), we demonstrated the involvement of LPG and
PGs in the leishmanicidal action of VIP51. Interestingly, both
mutants continued to express LPG fragments and an abundant
class of glycophosphatidylinositol lipids (GIPLs), which is
expressed in both the promastigote and amastigote stages (48).
The lpg2/ mutant expresses a Gal-Gal-Galf-Man-Man-
GlcN-Inos-P-lyso-alkyl glycerol (24) and normal levels of
GIPLs, whereas theGLFmutant should continue to express the
LPG fragment Man-Man-GlcN-Inos-P-lyso-alkyl glycerol as
well as truncatedGIPLs, which differ from the LPG fragment in
bearing an acyl-alkyl glycerol anchor (51). However, none of
these molecules (GIPL, truncated LPG, or truncated GIPLs)
seemed to be the target of the VIP analog. Further research will
define the selectivity of the peptides for certain Leishmania
strains based on the different complexity that exists in the sur-
face coat composition of these parasites. In contrast to the VIP
derivatives, VIP failed to kill any of the Leishmania strains
assayed, although it was able to bind to their cell surface (not
shown). Therefore, the capacity of theVIP derivatives to induce
the formation of pores in the membrane (probably through
their hydrophobic domains) must be a determinant in their
leishmanicidal activity. In fact, VIP was reported to kill other
trypanosomatids through a mechanism that does not involve
disruption of the cell membrane but rather the endocytosis of
VIP by the parasite and later disruption of intracellular targets
(15).
Our study has important therapeutic implications because
we demonstrated the efficacy of VIP51(6–30) in a model of
severe cutaneous leishmaniasis, in which the local injection of
VIP51(6–30) drastically reduced the cutaneous lesions, para-
site loads, and dissemination of the disease to visceral organs.
Surprisingly, despite its potent leishmanicidal action observed
in vitro, VIP51 did not efficiently protect from cutaneous leish-
maniasis. A possible explanation for this finding is that the par-
asite could use the anti-inflammatory and Th2 responses
induced byVIP51 to counteract the immune responsemounted
by the host against this intracellular parasite (52). However,
because VIP51(6–30) does not regulate immune responses in
the host, the therapeutic effect of VIP51(6–30) in vivo is prob-
ably exerted by killing the parasites released from infected cells
during lysis and reducing the density of the new infective
population.
In summary, due their effectiveness, salt resistance, and
speed of action against a variety of pathogens, VIP51 and
VIP51(6–30) show good potential for further studies and ratio-
nal design for development as antimicrobial agents. Moreover,
contrary to some current treatments, these novel target-spe-
cific peptides have shownminimal toxicity toward host cells, as
demonstrated in our study (hemolytic and cytotoxicity assays)
and in models of airway inflammatory diseases (20, 21). More-
over, we did not observe side effects, according to the criteria
established in the Guide for Laboratory Animal Care, with spe-
cial emphasis in the evaluation of symptoms related to diarrhea
and hypotension, which are two of the potential severe compli-
cations attributable to VIP overexposure. However, taking into
account the relevance of VIP51 to the modulation of immune
responses, precautions should be taken in considering how,
when, and which infections could be preferentially treated with
FIGURE 10. Immunological responses of animals suffering cutaneous
leishmaniasis. A, mice infected with L. major and treated with saline (con-
trol), VIP, or VIP51 showed enlarged lymph nodes and spleen compared with
the normal size of these lymphoid organs isolated from VIP51(6–30)-treated
mice. B, proliferation and cytokine production by draining lymph node cells
isolated (at 5 weeks postinfection) from mice infected with L. major and
treatedwith saline (control) or theVIPderivatives. Themean S.E. (error bars)
of three independent experiments (10 mice/group) is shown. *, p 0.05 ver-
sus untreated infected mice.
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each of these VIP derivatives. Targeting of the innate immunity
is an attractive approach because disease is a manifestation of
the ability of pathogens to overcome or subvert host immune
responses. However, although therapeutic agents with an
immunomodulatory role are very attractive for treatment of
patients with severe sepsis and high risk of death (53), such
agents may interrupt protective host defense mechanisms or
produce other deleterious effects that result in a worse out-
come. On the other hand, the infection with Leishmania can be
frequently accompanied by immunosuppression. This indi-
cates that therapies directed to clear the primary infection and
to avoid the development of secondary infections may be more
attractive. Finally, by targetingmembrane components that are
critical for the pathogen, these peptides may overcome the
resistance observed with existing drugs and could be used in
combination with other therapeutics.
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Supplemental Figures  
Figure S1. Structural properties of native VIP, VIP51 and VIP51(6-30). For each peptide, top 
images: ribbon schemes with side chains of amino acids; bottom images: predicted molecular 
surface model showing theoretical distribution of charges in the surface. The molecular 
modelling of VIP and VIP derivatives was resolved in the I-TASSER server. Distribution of 
charged amino acids in ribbon models and in 3D surfaces was visualized using the Pisson-
Boltzman algorithm of Swiss Protein Data Bank viewer v4.0.4 (http://spdbv.vital-
it.ch/refs.html). Negative residues (red), positive residues (dark-blue), polar residues (pink), and 
apolar residues (light-blue). 
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Table S1. Specific hydrogen-bonding contacts between VIP and D21”Ra” 
 
Positiona VIP FTT PO4 DPO PA1 GCN KDO GMH GLC GLA ∑Aab %Aac 
1 H                     
2 S                     
3 D               2 1 3 10.3 
4 A                     
5 V                     
6 F                     
7 T         1 2       3 10.3 
8 D           1       1 3.4 
9 N                     
10 Y                     
11 T     1     2   1   4 13.8 
12 R     2         1   3 10.3 
13 L                     
14 R 3 3 1       1     8 27.6 
15 K 1 1   2       2   6 20.7 
16 Q 1                 1 3.4 
17 M                     
18 A                     
19 V                     
20 K                     
21 K                     
22 Y                     
23 L                     
24 N                     
25 S                     
26 I                     
27 L                     
28 N                     
 ∑Chd 5 4 4 2 1 5 1 6 1   
 %Che 17 14 14 7 3 17 3 21 3   
 
a Position of each amino acid in the sequence of the VIP molecule. 
b Summation of hydrogen-bonding contacts between specific amino acids of VIP and D21”Ra”. 
c % of total hydrogen-bonding amino acid implicated in the interaction between VIP and 
D21”Ra”. 
d Summation of the total of hydrogen-bonding implicated in the interaction between each 
carbohydrate residue with VIP. 
e % of total hydrogen-bonding carbohydrate residue implicated in the interaction with VIP. 
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Table S2. Specific hydrogen-bonding contacts between VIP51 and D21”Ra”. 
 
Positiona VIP51 FTT PO4 DPO PA1 GCN KDO GMH GLC GLA ∑Aab %Aac 
1 H               1   1 2.6 
2 S               4 2 6 15.8 
3 D                      
4 A                      
5 V                 1 1 2.6 
6 F                      
7 T                      
8 A 1                 1 2.6 
9 N     6             6 15.8 
10 Y                      
11 T       1           1 2.6 
12 R 7 2 1 1   3       14 36.8 
13 L                      
14 R   2               2 5.3 
15 R     1     3   1   5 13.2 
16 Q 1                 1 2.6 
17 L                     
18 A                     
19 V                     
20 R                     
21 R                     
22 Y                     
23 L                     
24 A                     
25 A                     
26 I                     
27 L                     
28 G                     
29 R                     
30 R                     
 ∑Chd 9 4 8 2 0 6 0 6 3   
 %Che 24 11 21 5 0 16 0 16 8   
 
a Position of each amino acid in the sequence of the VIP51 molecule. 
b Summation of hydrogen-bonding contacts between specific amino acids of VIP51 and 
D21”Ra”. 
c % of total hydrogen-bonding amino acid implicated in the interaction between VIP51 and 
D21”Ra”. 
d Summation of the total of hydrogen-bonding implicated in the interaction between each 
carbohydrate residue with VIP51. 
e % of total hydrogen-bonding carbohydrate residue implicated in the interaction with VIP51. 
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Table S3. Specific hydrogen-bonding contacts between VIP51(6-30) and D21”Ra”. 
 
Positiona VIP51(6-30) FTT PO4 DPO PA1 GCN KDO GMH GLC GLA ∑Aab %Aac 
6 F                     
7 T                     
8 A               1   1 2 
9 N                 1 1 2 
10 Y                 1 1 2 
11 T           1   1   2 4 
12 R 1   2 2   3       8 16 
13 L                     
14 R       1   2   1 2 6 12 
15 R 1 2 1   1 10   5   20 40 
16 Q 1         1       2 4 
17 L                     
18 A                     
19 V                     
20 R     1     2 1     4 8 
21 R 1         2       3 6 
22 Y                     
23 L                     
24 A                     
25 A                     
26 I                     
27 L                     
28 G                     
29 R 1             1   2 4 
30 R                     
 ∑Chd 5 2 4 3 1 21 1 9 4   
 %Che 10 4 8 6 2 42 2 18 8   
 
a Position of each amino acid in the sequence of the VIP51(6-30) molecule. 
b Summation of hydrogen-bonding contacts between specific amino acids of VIP51(6-30) and 
D21”Ra”. 
c % of total hydrogen-bonding amino acid implicated in the interaction between VIP51(6-30) and 
D21”Ra”. 
d Summation of the total of hydrogen-bonding implicated in the interaction between each 
carbohydrate residue with VIP51(6-30). 
e % of total hydrogen-bonding carbohydrate residue implicated in the interaction with VIP51(6-
30). 
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Table S4. Specific hydrogen-bonding contacts between VIP and D21f2”Rd” 
 
Positiona VIP FTT PO4 DPO PA1 GCN KDO ∑Aab %Aac 
1 H                
2 S                
3 D           2 2 5.6 
4 A                
5 V                
6 F                
7 T 1           1 2.8 
8 D 2           2 5.6 
9 N                
10 Y                
11 T 5       1   6 16.7 
12 R 4         7 11 30.6 
13 L                
14 R 1 1 2 2   5 11 30.6 
15 K     1     1 2 5.6 
16 Q                
17 M                
18 A                
19 V                
20 K                
21 K     1       1 2.8 
22 Y               
23 L               
24 N               
25 S               
26 I               
27 L               
28 N               
 ∑Chd 13 1 4 2 1 15   
 %Che 36 3 11 6 3 42   
 
a  Position of each amino acid in the sequence of the VIP molecule. 
b Summation of hydrogen-bonding contacts between specific amino acids of VIP and 
D21F2”Rd”. 
c % of total hydrogen-bonding amino acid implicated in the interaction between VIP and 
D21f2”Rd”. 
d Summation of the total of hydrogen-bonding implicated in the interaction between each 
carbohydrate residue with VIP. 
e % of total hydrogen-bonding carbohydrate residue implicated in the interaction with VIP. 
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Table S5. Specific hydrogen-bonding contacts between VIP51 and D21f2”Rd” 
 
Positiona VIP51 FTT PO4 DPO PA1 GCN KDO ∑Aab %Aac 
1 H 2         3 5 11.4 
2 S 1         1 2 4.5 
3 D         1 1 2 4.5 
4 A                
5 V           1 1 2.3 
6 F                
7 T                
8 A           1 1 2.3 
9 N     4 1   3 8 18.2 
10 Y                
11 T 1           1 2.3 
12 R 3         1 4 9.1 
13 L                
14 R 3           3 6.8 
15 R       1 1 1 3 6.8 
16 Q                
17 L                
18 A                
19 V               
20 R                
21 R     1 1 1 7 10 22.7 
22 Y 1           1 2.3 
23 L                
24 A                
25 A                
26 I                
27 L                
28 G                
29 R 2 1         3 6.8 
30 R               
 ∑Chd 13 1 5 3 3 19   
 %Che 31 2 11 7 7 43   
 
a Position of each amino acid in the sequence of the VIP51 molecule. 
b Summation of hydrogen-bonding contacts between specific amino acids of VIP51 and 
D21f2”Rd”. 
c % of total hydrogen-bonding amino acid implicated in the interaction between VIP51 and 
D21f2”Rd”. 
d Summation of the total of hydrogen-bonding implicated in the interaction between each 
carbohydrate residue with VIP51. 
e % of total hydrogen-bonding carbohydrate residue implicated in the interaction with VIP51. 
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Table S6. Specific hydrogen-bonding contacts between VIP51(6-30) and D21f2”Rd” 
 
Positiona VIP51f FTT PO4 DPO PA1 GCN KDO ∑Aab %Aac 
6 F               
7 T               
8 A               
9 N     2     1 3 9.4 
10 Y                
11 T                
12 R 1           1 3.1 
13 L                
14 R 2   1 1     4 12.5 
15 R           1 1 3.1 
16 Q                
17 L                
18 A                
19 V                
20 R                
21 R     1 1 2 8 12 37.5 
22 Y                
23 L                
24 A                
25 A                
26 I                
27 L                
28 G                
29 R 2 1         3 9.4 
30 R       1   7 8 25.0 
  ∑Chd 5 1 4 3 2 17   
 %Che 15 3 12 9 6 53   
 
a Position of each amino acid in the sequence of the VIP51(6-30) molecule. 
b Summation of hydrogen-bonding contacts between specific amino acids of VIP51(6-30) and 
D21”Ra”. 
c % of total hydrogen-bonding amino acid implicated in the interaction between VIP51(6-30) and 
D21”Ra”. 
d Summation of the total of hydrogen-bonding implicated in the interaction between each 
carbohydrate residue with VIP51(6-30). 
e % of total hydrogen-bonding carbohydrate residue implicated in the interaction with VIP51(6-
30). 
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